Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib vs Temozolomide in Metastatic Uveal Melanoma
NCT01143402Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2010
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of selumetinib in Uveal melanoma (UM), sponsored by National Cancer Institute. Started Jun 2010; status: completed.
02
Drugs
selumetinib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01143402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01143402.